Town Hall Seattle Science Series
Jul 27, 2026 · 1 hr 15 min · 12 segments
 Grief is one of the most…
Sunil AggarwalGuest
April PrideHost
So, yeah, the last piece actually is very, very topical, and that is the president's executive order from earlier.

And Right to Try was sort of like a blip in all of that, if you were paying attention.

And Dr. Agarwal is the first to petition the DEA for Right to Try for his patients to be able to use psilocybin for end of life.

Back in 2000, we started, I worked with a wonderful attorney named Catherine Tucker.

She's argued cases before the Supreme Court on the rights for terminally ill patients to have the right to die and our right to withhold treatments and medical aid in dying, things like that.

She's really passionate about making life meaningful even if your life span is limited and you know it, but you're still alive and you still have autonomy, you have choices, And she realized that because of the studies that were done at NYU and other places that psilocybin had a huge role to play in helping people deal with that challenging time when they get a terminal diagnosis.

We teamed up through this organization called End of Life Washington that I was part of.

She asked me if I had patients who might want to try psilocybin who are dealing with that.

In my clinic, Ames Institute, we have integrative oncology track, and so I had a number of patients that were that were interested, but most people didn't know what to do, but she said, well, I think I know how to, we just asked them, you know, because there was really no pathway, but it made sense to her, and it turned out it became a big legal argument between the, you know, DEA's definition of, well, the Schedule 1 doesn't apply to right to try, even though the right to try law, which is a You know, Food Drug Cosmetic Act law says any drug that's passed phase one clinical trials, if it's safe, it's eligible to be used as long as you have informed consent and as long as you have a manufacturer willing to provide it to you.

We argued that and we had two or three Ninth Circuit case hearings and ultimately we ended up having to file a petition to reschedule psilocybin from Schedule 1 to Schedule 2 is what we asked for based on so much data and there's even like Johns Hopkins researchers had written a paper specifically on this.

He was one of the pioneering researchers in this field and he actually had stage four, I believe, colon cancer and he interviewed with the New York Times and he said that he also used psychedelics at the end of his life there and how much profound the healing it was for him.

He already knew that he was, you know, not taking any further cancer treatment.

So, yeah, the last piece actually is very, very topical, and that is the president's executive order from earlier.

And Right to Try was sort of like a blip in all of that, if you were paying attention.

And Dr. Agarwal is the first to petition the DEA for Right to Try for his patients to be able to use psilocybin for end of life.

Back in 2000, we started, I worked with a wonderful attorney named Catherine Tucker.

She's argued cases before the Supreme Court on the rights for terminally ill patients to have the right to die and our right to withhold treatments and medical aid in dying, things like that.

She's really passionate about making life meaningful even if your life span is limited and you know it, but you're still alive and you still have autonomy, you have choices, And she realized that because of the studies that were done at NYU and other places that psilocybin had a huge role to play in helping people deal with that challenging time when they get a terminal diagnosis.

We teamed up through this organization called End of Life Washington that I was part of.

She asked me if I had patients who might want to try psilocybin who are dealing with that.

In my clinic, Ames Institute, we have integrative oncology track, and so I had a number of patients that were that were interested, but most people didn't know what to do, but she said, well, I think I know how to, we just asked them, you know, because there was really no pathway, but it made sense to her, and it turned out it became a big legal argument between the, you know, DEA's definition of, well, the Schedule 1 doesn't apply to right to try, even though the right to try law, which is a You know, Food Drug Cosmetic Act law says any drug that's passed phase one clinical trials, if it's safe, it's eligible to be used as long as you have informed consent and as long as you have a manufacturer willing to provide it to you.

We argued that and we had two or three Ninth Circuit case hearings and ultimately we ended up having to file a petition to reschedule psilocybin from Schedule 1 to Schedule 2 is what we asked for based on so much data and there's even like Johns Hopkins researchers had written a paper specifically on this.

He was one of the pioneering researchers in this field and he actually had stage four, I believe, colon cancer and he interviewed with the New York Times and he said that he also used psychedelics at the end of his life there and how much profound the healing it was for him.

He already knew that he was, you know, not taking any further cancer treatment.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.